{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:42Z","timestamp":1791613662043,"version":"4.3.4"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Obesity and obesogenic behaviors are positively associated with both monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM). As the only known modifiable risk factor, this association has emerged as a new potential target for MM prevention, but little is known about the mechanistic relationship of body weight with MM progression. Here we summarize epidemiological correlations between weight, body composition, and the various stages of myeloma disease progression and treatments, as well as the current understanding of the molecular contributions of obesity-induced changes in myeloma cell phenotype and signaling. Finally, we outline groundwork for the future characterization of the relationship between body weight patterns, the bone marrow microenvironment, and MM pathogenesis in animal models, which have the potential to impact our understanding of disease pathogenesis and inform MM prevention messages.<\/jats:p>","DOI":"10.3389\/fendo.2023.1118691","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:41:44Z","timestamp":1677138104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Obesity and myeloma: Clinical and mechanistic contributions to disease progression"],"prefix":"10.3389","volume":"14","author":[{"given":"Constance","family":"Marques-Mourlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Fairfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela R.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","unstructured":"Key statistics for multiple myeloma"},{"key":"B2","unstructured":"Adult obesity facts | overweight & obesity"},{"key":"B3","unstructured":"Obesity and cancer fact sheet - NCI"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/291546","article-title":"Obesity as a major risk factor for cancer","volume":"2013","author":"De Pergola","year":"2013","journal-title":"J Obes"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsr1606602","article-title":"Body fatness and cancer \u2014 viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz054","article-title":"Intentional weight loss and obesity-related cancer risk","volume":"3","author":"Luo","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21101\/cejph.a5913","article-title":"Impact of obesity on risk of cancer","volume":"29","author":"Krupa-Kotara","year":"2021","journal-title":"Cent Eur J Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/S40610-018-0096-8","article-title":"Molecular interaction of bone marrow adipose tissue with energy metabolism","volume":"4","author":"Suchacki","year":"2018","journal-title":"Curr Mol Biol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/NM.4297","article-title":"The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue","volume":"23","author":"Lynes","year":"2017","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00683-w","article-title":"Mitochondrial RNA stimulates beige adipocyte development in young mice","volume":"4","author":"Hoang","year":"2022","journal-title":"Nat Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.29245\/2578-3025\/2019\/4.1174","article-title":"Human perivascular adipose tissue as a regulator of the vascular microenvironment and diseases of the coronary artery and aorta","volume":"3","author":"Stieber","year":"2019","journal-title":"J Cardiol Cardiovasc Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24954","article-title":"A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL\/6J mice","volume":"230","author":"Doucette","year":"2015","journal-title":"J Cell Physiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.01.008","article-title":"Development, regulation, metabolism and function of bone marrow adipose tissues","volume":"110","author":"Li","year":"2018","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24221","article-title":"The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern cooperative oncology","volume":"115","author":"Kyle","year":"2009","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet (London England)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-016-2425-4","article-title":"Abdominal adipose tissue in MGUS and multiple myeloma","volume":"45","author":"Veld","year":"2016","journal-title":"Skeletal Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017007609","article-title":"Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study","volume":"1","author":"Thordardottir","year":"2017","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based cohort study","volume":"109","author":"Chang","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/S41408-022-00642-4","article-title":"Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the prostate, lung, colorectal and ovarian cancer screening trial","volume":"12","author":"Chang","year":"2022","journal-title":"Blood Cancer J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0010-4","article-title":"Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts","volume":"118","author":"Marinac","year":"2018","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz044","article-title":"Elucidating under-studied aspects of the link between obesity and multiple myeloma: Weight pattern, body shape trajectory, and body fat distribution","volume":"3","author":"Marinac","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12935","article-title":"Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies","volume":"166","author":"Teras","year":"2014","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.01.020","article-title":"Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies","volume":"47","author":"Wallin","year":"2011","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw120","article-title":"Multiple myeloma mortality in relation to obesity among African americans","volume":"108","author":"Sonderman","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14215331\/S1","article-title":"Body mass index and overall survival of patients with newly diagnosed multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLML.2017.03.252","article-title":"Influence of obesity on outcomes of patients with relapsed refractory multiple myeloma","volume":"17","author":"Roy","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.05.005","article-title":"Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"17","author":"Vogl","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.CANEP.2016.01.003","article-title":"Obesity and cancer: An update of the global impact","volume":"41","author":"Arnold","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/JH536","article-title":"C-reactive protein level: A key predictive marker of cachexia in lymphoma and myeloma patients","volume":"8","author":"Mallard","year":"2019","journal-title":"J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE13528","article-title":"Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/TCR.2020.03.36","article-title":"Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/NRCLINONC.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2021.278772","article-title":"Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls","volume":"107","author":"Shah","year":"2022","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/JDI.13940","article-title":"Impact of coexisting diabetes on survival and risk of developing second primary cancer in diabetes patients receiving drug therapy: A multicenter retrospective cohort study of patients with cancer in Japan","volume":"14","author":"Kuwabara","year":"2023","journal-title":"J Diabetes Investig"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/CANCERS12113226","article-title":"The acidic microenvironment: Is it a phenotype of all cancers? a focus on multiple myeloma and some analogies with diabetes mellitus","volume":"12","author":"Fais","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6615684","article-title":"Obesity as a possible risk factor for progression from monoclonal gammopathy of undetermined significance progression into multiple myeloma: Could myeloma be prevented with metformin treatment","volume":"2021","author":"da Cunha J\u00fanior","year":"2021","journal-title":"Adv Hematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1236375","article-title":"Impact of metformin on the progression of MGUS to multiple myeloma","volume":"58","author":"Boursi","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.3390\/CANCERS14225637","article-title":"The risk of multiple myeloma is reduced in metformin initiators: A retrospective cohort study in Taiwanese patients with type 2 diabetes mellitus","volume":"14","author":"Tseng","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-018-0731-5","article-title":"Metformin induces autophagy and G0\/G1 phase cell cycle arrest in myeloma by targeting the AMPK\/mTORC1 and mTORC2 pathways","volume":"37","author":"Wang","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2022.2062895","article-title":"Metformin induces myeloma cells necrosis and apoptosis and it is considered for therapeutic use","author":"Wu","year":"2022","journal-title":"J Chemother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00299","article-title":"Metformin affects cortical bone mass and marrow adiposity in diet-induced obesity in male mice","volume":"158","author":"Bornstein","year":"2017","journal-title":"Endocrinology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/J.LFS.2022.121092","article-title":"Metformin suppresses oxidative stress induced by high glucose via activation of the Nrf2\/HO-1 signaling pathway in type 2 diabetic osteoporosis","volume":"312","author":"Chen","year":"2023","journal-title":"Life Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2021.101301","article-title":"The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden","volume":"15","author":"G\u00e1mez","year":"2022","journal-title":"Vivo Transl Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLML.2020.07.003","article-title":"Statins reduce mortality in multiple myeloma: A population-based US study","volume":"20","author":"Afzal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.gastro.2021.03.021","article-title":"Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity","volume":"161","author":"Rustgi","year":"2021","journal-title":"Gastroenterology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.34011","article-title":"Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study","volume":"151","author":"Sun","year":"2022","journal-title":"Int J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/S13679-021-00426-0\/FIGURES\/1","article-title":"Gender differences in obesity-related cancers","volume":"10","author":"Argyrakopoulou","year":"2021","journal-title":"Curr Obes Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/J.BONE.2023.116682","article-title":"Antibodies to sclerostin or G-CSF receptor partially eliminate bone or marrow adipocyte loss, respectively, following vertical sleeve gastrectomy","volume":"169","author":"Li","year":"2023","journal-title":"Bone"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/J.BONE.2022.116608","article-title":"The PYY\/Y2R-deficient male mouse is not protected from bone loss due to roux-en-Y gastric bypass","volume":"167","author":"Zahedi","year":"2023","journal-title":"Bone"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/J.JNUTBIO.2014.06.013","article-title":"Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells","volume":"25","author":"Abdi","year":"2014","journal-title":"J Nutr Biochem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bonekey.2015.142","article-title":"Preclinical animal models of multiple myeloma","volume":"5","author":"Lwin","year":"2016","journal-title":"Bonekey Rep"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/j.clml.2019.09.142","article-title":"Investigation of the relationship between obesity, weight cycling, and tumor progression in a myeloma xenograft model","volume":"19","author":"Campbell","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.295","article-title":"Diet-induced obesity promotes a myeloma-like condition","volume":"29","author":"Lwin","year":"2015","journal-title":"Vivo Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","article-title":"Acetyl-CoA synthetase 2: A critical linkage in obesity-induced tumorigenesis in myeloma","volume":"33","author":"Li","year":"2021","journal-title":"Cell Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6020","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3408","article-title":"High-fat diet\u2013induced obesity promotes expansion of bone marrow adipose tissue and impairs skeletal stem cell functions in mice","volume":"33","author":"Tencerova","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030364","article-title":"Bone marrow adipocytes: A link between obesity and bone cancer","volume":"13","author":"Reagan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEEM.2021.101564","article-title":"Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment","volume":"35","author":"Tratwal","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404658","article-title":"Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells","volume":"21","author":"Caers","year":"2007","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584683","article-title":"Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes","volume":"10","author":"Fairfield","year":"2021","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00067","article-title":"Signaling interplay between bone marrow adipose tissue and multiple myeloma cells","volume":"7","author":"Falank","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9087","article-title":"Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease","volume":"11","author":"Liu","year":"2019","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3951","article-title":"Myeloma cells down-regulate adiponectin in bone marrow adipocytes Via TNF-alpha","volume":"35","author":"Morris","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype","volume":"81","author":"Fairfield","year":"2021","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021013832","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"139","author":"Panaroni","year":"2022","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.07.012","article-title":"Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone","volume":"186","author":"Trotter","year":"2016","journal-title":"Am J Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912834","article-title":"Development and characterization of three cell culture systems to investigate the relationship between primary bone marrow adipocytes and myeloma cells","volume":"12","author":"Fairfield","year":"2022","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2018.01.023","article-title":"Development of a 3D bone marrow adipose tissue model","volume":"118","author":"Fairfield","year":"2018","journal-title":"Bone"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0773","article-title":"CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma","volume":"79","author":"Marlein","year":"2019","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33497","article-title":"Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma","volume":"148","author":"Polusani","year":"2021","journal-title":"Int J Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/S00277-007-0375-6","article-title":"Cholesterol levels in patients with multiple myeloma","volume":"87","author":"Yavasoglu","year":"2008","journal-title":"Ann Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.7150\/JCA.69321","article-title":"A new prediction model integrated serum lipid profile for patients with multiple myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.15653","article-title":"Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors","volume":"178","author":"Xu","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/BLOODADVANCES.2020002578","article-title":"The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma","volume":"5","author":"Lipchick","year":"2021","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2020-141994","article-title":"Acyl-CoA synthetase long chain family inhibition with triacsin c inhibits multiple myeloma cell proliferation and survival","volume":"136","author":"Murphy","year":"2020","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142512","article-title":"Targeting bone marrow adipose tissue and the FABP family increases efficacy of dexamethasone in multiple myeloma","volume":"136","author":"Farrell","year":"2020","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1101\/2022.07.01.498411","article-title":"The fatty acid binding protein family represents a novel target in multiple myeloma","author":"Farrell","year":"2022","journal-title":"bioRxiv"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/BLOOD-2021-152686","article-title":"Acid ceramidase (ASAH1) mediates intrinsic and intercellular transfer of proteasome inhibitor resistance in multiple myeloma","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/OL.2022.13231","article-title":"Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment","volume":"23","author":"Tanaka","year":"2022","journal-title":"Oncol Lett"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10173","article-title":"Multiple myeloma and fatty acid metabolism","volume":"3","author":"Masarwi","year":"2019","journal-title":"JBMR Plus"},{"key":"B87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/S40164-022-00303-Z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1336","article-title":"Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans","volume":"145","author":"Fain","year":"2004","journal-title":"Endocrinology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nm1195-1155","article-title":"Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects","volume":"1","author":"Maffei","year":"1995","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01311.x","article-title":"Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma","volume":"83","author":"Reseland","year":"2009","journal-title":"Eur J Haematol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.8.2442","article-title":"Adiponectin: More than just another fat cell hormone","volume":"26","author":"Chandran","year":"2003","journal-title":"Diabetes Care"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-008-9233-7","article-title":"Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study","volume":"20","author":"Dalamaga","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438606","article-title":"A prospective study of circulating adipokine levels and risk of multiple myeloma","volume":"120","author":"Hofmann","year":"2012","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330407","article-title":"Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease","volume":"118","author":"Fowler","year":"2011","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-50591-5","article-title":"Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment","volume":"9","author":"Olechnowicz","year":"2019","journal-title":"Sci Rep"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4475","article-title":"Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma","volume":"45","author":"Liu","year":"2020","journal-title":"Int J Mol Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154062","article-title":"Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression","volume":"102","author":"Pang","year":"2017","journal-title":"Haematologica"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01443-7","article-title":"A comprehensive review of the impact of obesity on plasma cell disorders","volume":"36","author":"Parikh","year":"2022","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2066","article-title":"Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells","volume":"103","author":"Qiang","year":"2004","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v96.8.2856.h8002856_2856_2861","article-title":"Insulin-like growth factor I is a dual effector of multiple myeloma cell growth","volume":"96","author":"Ge","year":"2000","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2000.02364.x","article-title":"Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway","volume":"111","author":"Ferlin","year":"2000","journal-title":"Br J Haematol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2478\/JOMB-2019-0009","article-title":"The relationship between sex steroids, insulin resistance and body compositions in obese women: A case-control study","volume":"39","author":"Sayln","year":"2020","journal-title":"J Med Biochem"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/J.FERTNSTERT.2005.10.054","article-title":"Obesity and androgens: facts and perspectives","volume":"85","author":"Pasquali","year":"2006","journal-title":"Fertil Steril"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1538511","article-title":"Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC","volume":"60","author":"Ozerova","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/JBMR.4507","article-title":"Estrogen-responsive gene MAST4 regulates myeloma bone disease","volume":"37","author":"Cui","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.M105185200","article-title":"Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3","volume":"276","author":"Wang","year":"2001","journal-title":"J Biol Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B111","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/TCMJ.TCMJ_141_20","article-title":"The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma","volume":"33","author":"Liu","year":"2021","journal-title":"Tzu-Chi Med J"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBADIS.2012.08.011","article-title":"Impact of obesity on IL-12 family gene expression in insulin responsive tissues","volume":"1832","author":"Nam","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000058","article-title":"Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells","volume":"25","author":"Wang","year":"2014","journal-title":"Anticancer Drugs"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"B115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","article-title":"Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism","volume":"3","author":"Elia","year":"2021","journal-title":"Nat Metab"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009617666170214102301","article-title":"Multiple myeloma and the immune microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","article-title":"Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity","volume":"183","author":"Ringel","year":"2020","journal-title":"Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210042","article-title":"Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function","volume":"219","author":"Dyck","year":"2022","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.65553","article-title":"Bone marrow adipocytes drive the development of tissue invasive Ly6Chigh monocytes during obesity","volume":"11","author":"Boroumand","year":"2022","journal-title":"Elife"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914956","article-title":"C1QTNF3 is upregulated during subcutaneous adipose tissue remodeling and stimulates macrophage chemotaxis and M1-like polarization","volume":"13","author":"Micallef","year":"2022","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e0127828","DOI":"10.1371\/journal.pone.0127828","article-title":"Whole genome sequence of multiple myeloma-prone C57BL\/KaLwRij mouse strain suggests the origin of disease involves multiple cell types","volume":"10","author":"Amend","year":"2015","journal-title":"PloS One"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00294","article-title":"Obesity-induced changes in bone marrow homeostasis","volume":"11","author":"Benova","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/J.CELREP.2019.04.066","article-title":"Obesity-associated hypermetabolism and accelerated senescence of bone marrow stromal stem cells suggest a potential mechanism for bone fragility","volume":"27","author":"Tencerova","year":"2019","journal-title":"Cell Rep"},{"key":"B126","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/oby.2010.106","article-title":"Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women","volume":"19","author":"Bredella","year":"2011","journal-title":"Obesity"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4385","article-title":"Targeting cellular senescence prevents age-related bone loss in mice","volume":"23","author":"Farr","year":"2017","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2022.01.003","article-title":"Cell senescence and malignant transformation in the inherited bone marrow failure syndromes: Overlapping pathophysiology with therapeutic implications","volume":"59","author":"Groarke","year":"2022","journal-title":"Semin Hematol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-170571","article-title":"MGUS and SMM plasma cells exhibit a senescence-like phenotype and accumulation of transposable elements that may contribute to disease progression","volume":"140","author":"Alvares Borges","year":"2022","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1111\/ACEL.12950","article-title":"Targeting senescent cells alleviates obesity-induced metabolic dysfunction","volume":"18","author":"Palmer","year":"2019","journal-title":"Aging Cell"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1118691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:41:51Z","timestamp":1677138111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1118691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":131,"alternative-id":["10.3389\/fendo.2023.1118691"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1118691","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1118691"}}